Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death. Methods We did a double-masked, randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Findings Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p=…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an 11% reduction in myocardial infarction (MI)”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“This study showed that each 10 mm Hg decrease in systolic BP (achieved with either an ACE inhibitor [captopril] or a beta blocker [atenolol]) was associated with a 15% reduction in DM-related mortality”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“and a 13% reduction in the microvascular complications of retinopathy or DKD.186”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Clinical trial data show that intensifying therapy with BP-lowering medications slows the progression of DKD and retinopathy, though vigilance in monitoring renal function during intensive BP therapy is recommended.185,186,201–203”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Optimization of glucose and BP are the proven strategies for primary prevention of diabetic retinopathy and for slowing the progression of preexisting nonproliferative retinopathy.78,185,186,193,522,523”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Self-citationMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
The Norwegian Multicenter Study Group (1981) · New England Journal of Medicine · doi:10.1056/nejm198104023041401 · Cited by 1,675
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Self-citationReversal of Left Ventricular Hypertrophy in Hypertensive Patients
Dahlöf, B., Pennert, K., & Hansson, L. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.2.95 · Cited by 925
Self-citationLemon, D. (1987) · The Journal of Emergency Medicine · doi:10.1016/0736-4679(87)90192-2 · Cited by 563
Research works printed but not linked: 2
- Dhlöf, 1997, The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods, Am J Hypertens, 10, 705
- Mulrow, 2001, Pharmacotherapy for hypertension in the elderly (Cochrane review)
Cited by
Items 901–1,000 of 1,018
Kelly, D. J., Cox, A. J., Gow, R. M., Zhang, Y., Kemp, B. E., & Gilbert, R. E. (2004) · Hypertension · doi:10.1161/01.hyp.0000132883.20764.12 · Cited by 72
Compulsory screening of immigrants for tuberculosis and HIV
Coker, R. (2004) · BMJ · doi:10.1136/bmj.328.7435.298 · Cited by 70
Effectiveness, safety and cost of drug substitution in hypertension
Johnston, A. E., Stafylas, P. C., & Stergiou, G. S. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03681.x · Cited by 69
Angiotensin receptor blockers and cerebral protection in stroke
Thöne‐Reineke, C., Steckelings, U. M., & Unger, T. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000220416.07235.37 · Cited by 69
ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney
Wysocki, J. A., Ortiz-Melo, D. I., Mattocks, N. K., Xu, K. H., Prescott, J., Evora, K., Ye, M., Sparks, M. A., Haque, S. K., BATLLE, D. C., et al. (2014) · Physiological Reports · doi:10.1002/phy2.264 · Cited by 69
Pershadsingh, H. A. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.08.006 · Cited by 69
Morin, D. P., Oikarinen, L., Viitasalo, M. T., Toivonen, L., Nieminen, M. S., Kjeldsen, S., Dahlöf, B., John, M., Devereux, R. B., & Okin, P. M. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp321 · Cited by 69
Self-citationLeys, D., Kwieciński, H., Bogousslavsky, J., Bath, P. M., Brainin, M., Diener, H., Kaste, M., Sivenius, J., Hennerici, M. G., & Hacke, W. (2004) · Cerebrovascular Diseases · doi:10.1159/000074817 · Cited by 71
Ghosh, S., Rana, A., & Biswas, S. (2023) · Chemistry of Materials · doi:10.1021/acs.chemmater.3c02459 · Cited by 69
Makita, S., Abiko, A., Naganuma, Y., Moriai, Y., & Nakamura, M. (2008) · Metabolism · doi:10.1016/j.metabol.2008.05.019 · Cited by 69
Review of blood pressure control rates and outcomes
Bakris, G. L., Sarafidis, P. A., Agarwal, R., & Ruilope, L. M. (2013) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2013.07.009 · Cited by 68
Elliott, W. J. (2006) · Yearbook of Cardiology · doi:10.1016/s0145-4145(07)70013-8 · Cited by 68
Boulanger, J.-M., & Hill, M. D. (2006) · Stroke · doi:10.1161/01.str.0000199659.31103.d2 · Cited by 68
Convergence of Protein Kinase C and JAK-STAT Signaling on Transcription Factor GATA-4
Wang, J., Paradis, P., Aries, A., Komati, H., Lefebvre, C., Wang, H., & Nemer, M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.9829-9844.2005 · Cited by 68
Poulter, N. R., Dobson, J. E., Sever, P., Dahlöf, B., Wedel, H., & Campbell, N. R. C. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.087 · Cited by 68
Self-citationJiang, X., O’Rourke, M. F., Zhang, Y., He, X., & Liu, L. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280ac1533 · Cited by 68
Min, L.-J., Mogi, M., Tsukuda, K., Jing, F., Ohshima, K., Nakaoka, H., Kan-no, H., Wang, X.-L., Chisaka, T., Bai, H.-Y., et al. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpu015 · Cited by 68
Devereux, R. B., Dahlf, B., Kjeldsen, S. E., Julius, S., Aurup, P., Beevers, G., Edelman, J. M., de Faire, U., Fyhrquist, F., Berg, S. H., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-3-200308050-00006 · Cited by 68
Self-citationEvidence-based medicine in hypertension: what type of evidence?
Zanchetti, A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000170370.41387.1b · Cited by 68
Metabolic syndrome: Evaluation of pathological and therapeutic outcomes
Miranda, P. J., DeFronzo, R. A., Califf, R. M., & Guyton, J. R. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.012 · Cited by 69
Os, I., Franco, V., Kjeldsen, S. E., Manhem, K., Devereux, R. B., Gerdts, E., Hille, D. A., Lyle, P. A., Okin, P. M., Dahlöf, B., et al. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.105296 · Cited by 68
Self-citationAngiotensin Receptor Blockers: Current Status and Future Prospects
Ram, C. V. S. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.02.038 · Cited by 68
Safety of Telmisartan in Patients with Arterial Hypertension: An Open-Label Observational Study
Michel, M. C., Bohner, H., K??ster, J., fers, R. F. S., & Heemann, U. W. (2004) · Drug Safety · doi:10.2165/00002018-200427050-00005 · Cited by 68
Current role of beta-blockers in the treatment of hypertension
Aronow, W. S. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.482561 · Cited by 68
Larstorp, A. C. K., Ariansen, I., Gjesdal, K., Olsen, M. H., Ibsen, H., Devereux, R. B., Okin, P. M., Dahlöf, B., Kjeldsen, S. E., & Wachtell, K. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195032 · Cited by 68
Self-citationAngiotensin receptors in the cardiovascular system.
Wagenaar, L. J., Voors, A. A., Buikema, H., & van Gilst, W. H. (2002) · PubMed · Cited by 68
Koh, K. K., Chung, W., Ahn, J. Y., Han, S. H., Kang, W. C., Seo, Y., Ahn, T. H., Choi, I. S., & Shin, E. K. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.07.008 · Cited by 68
Lacourcière, Y., Poirier, L., Daniel Hebert, Assouline, L., Stolt, P., Réhel, B., & Khder, Y. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.010 · Cited by 68
Translating statistical findings into plain English
Pocock, S. J., & Ware, J. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60499-2 · Cited by 67
Alter, P. J., Rupp, H., Stoll, F., Adams, P., Figiel, J. H., KLOSE, K. J., Rominger, M. B., & Maisch, B. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.07.092 · Cited by 67
Wachtell, K., Gerdts, E., Aurigemma, G. P., Boman, K., Dahlöf, B., Nieminen, M. S., Olsen, M. H., Okin, P. M., Palmieri, V., Rokkedal, J. E., et al. (2010) · Blood Pressure · doi:10.3109/08037051.2010.481811 · Cited by 67
Self-citationAldosterone Function in Diabetes Mellitus: Effects on Cardiovascular and Renal Disease
McFarlane, S. I., & Sowers, J. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021443 · Cited by 67
Madison, J. R., Spies, C., Schatz, I. J., Masaki, K., Chen, R., Yano, K., & Curb, J. D. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.8.884 · Cited by 67
Stroke Prevention: Managing Modifiable Risk Factors
Legge, S. D., Koch, G., Diomedi, M., Stanzione, P., & Sallustio, F. (2012) · Stroke Research and Treatment · doi:10.1155/2012/391538 · Cited by 67
Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome
Codario, R. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-441-8 · Cited by 68
Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options
Sayın, B. Y., & Oto, A. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00260-y · Cited by 67
Kim, E., Hwang, S.-H., Kim, H.-K., Abdi, S., & Kim, H. K. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1616-0 · Cited by 67
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Rosei, E., Azizi, M., Burnier, M., Clement, D., Coca, A., de Simone, G., Dominiczak, A. F., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.12.005 · Cited by 69
Self-citationKoh, K. K., Han, S. H., Oh, P. C., Shin, E. K., & Quon, M. J. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.09.007 · Cited by 67
(2014) · Hypertension Research · doi:10.1038/hr.2014.17 · Cited by 68
Obesity and Heart Failure — Risk Factor or Mechanism?
Massie, B. M. (2002) · New England Journal of Medicine · doi:10.1056/nejme020065 · Cited by 66
Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis
Kuyper, L. M., & Khan, N. A. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.01.006 · Cited by 66
Waeber, B. (2003) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.1.43 · Cited by 66
Beyond blood pressure: Arterial stiffness as a new biomarker of cardiovascular disease
Franklin, S. S. (2008) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2007.09.002 · Cited by 66
Bahadır, Ö., Uzunlulu, M., Oğuz, A., & Bahadır, M. A. (2007) · Hypertension Research · doi:10.1291/hypres.30.49 · Cited by 66
Losartan and Simvastatin Inhibit Platelet Activation in Hypertensive Patients
Nomura, S., Shouzu, A., Omoto, S., Nishikawa, M., Fukuhara, S., & Iwasaka, T. (2004) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-005-0343-8 · Cited by 66
Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments
Perini, M. V., Dmello, R. S., Nero, T. L., & Chand, A. L. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107527 · Cited by 66
Use of carvedilol in hypertension: an update
Egan, C. G., & Leonetti (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s31578 · Cited by 66
Cacciapuoti, F. (2011) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2011.08.006 · Cited by 66
Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in mice
Weng, L., Zhang, W.-B., Ye, Y., Yin, P., Yuan, J., Wang, X.-X., Kang, L., Jiang, S., You, J., Wu, J., et al. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.45 · Cited by 66
Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension
Ojha, U., Ruddaraju, S., Sabapathy, N., Ravindran, V., Worapongsatitaya, P., Haq, J., Mohammed, R., & Patel, V. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00510-9 · Cited by 65
Stephens, J. W., Dhamrait, S. S., Cooper, J. A., Acharya, J., Miller, G. J., Hurel, S. J., & Humphries, S. E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.09.002 · Cited by 65
Role of Antihypertensive Drugs in Arterial ‘De-Stiffening’ and Central Pulsatile Hemodynamics
Koumaras, C., Tzimou, M., Stavrinou, E., Griva, T., Gossios, T. D., Katsiki, N., Athyros, V. G., Mikhailidis, D. P., & Karagiannis, A. I. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11599040-000000000-00000 · Cited by 65
Antagonist of the Type-1 ANG II receptor prevents against LPS-induced septic shock in rats
Hagiwara, S., Iwasaka, H., Hidaka, S., Hasegawa, A., Koga, H., & Noguchi, T. (2009) · Intensive Care Medicine · doi:10.1007/s00134-009-1545-x · Cited by 65
Pontiroli, A. E., Pizzocri, P., Saibene, A., Girola, A., Koprivec, D., & Fragasso, G. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802733 · Cited by 65
Hypertension‐Related Morbidity and Mortality in African Americans—Why We Need to Do Better
Ferdinand, K. C., & Sounders, E. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.05295.x · Cited by 65
Sparks, M. A., Parsons, K. K., Stegbauer, J., Gurley, S. B., Vivekanandan‐Giri, A., Fortner, C. N., Snouwaert, J., Raasch, E. W., Griffiths, R. C., Haystead, T., et al. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.165274 · Cited by 65
Telmisartan: just an antihypertensive agent? A literature review
Destro, M., Cagnoni, F., Dognini, G. P., Galimberti, V., Taietti, C., Cavalleri, C., & Galli, E. G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.632367 · Cited by 65
Functional Selectivity in Adrenergic and Angiotensin Signaling Systems
Patel, C. B., Noor, N., & Rockman, H. A. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.067066 · Cited by 65
Tikellis, C., Cooper, M. E., & Thomas, M. C. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.08.007 · Cited by 65
Combination drug treatment in hypertension
Tsioufis, C. P., & Thomopoulos, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.011 · Cited by 65
Desai, C. S., Ning, H., & Lloyd‐Jones, D. M. (2011) · Heart · doi:10.1136/heartjnl-2011-300819 · Cited by 65
Kjeldsen, S. E., & Julius, S. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.037 · Cited by 65
Self-citationKjeldsen, S. E., Stålhammar, J., Hasvold, P., Bodegård, J., Olsson, U., & Russell, D. (2009) · Journal of Human Hypertension · doi:10.1038/jhh.2009.77 · Cited by 65
Self-citationUse of Nonantiarrhythmic Drugs for Prevention of Sudden Cardiac Death
ALBERTE, C., & ZIPES, D. P. (2003) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.14.s9.23.x · Cited by 64
The end of β blockers for uncomplicated hypertension?
Beevers, D. G. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67575-7 · Cited by 64
Beta-Blockade Mitigates Exercise Blood Pressure in Hypertensive Male Patients
Kokkinos, P. F., Chrysohoou, C. A., Panagiotakos, D. B., Narayan, P., Greenberg, M. D., & Singh, S. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.057 · Cited by 64
Drug-induced diabetes mellitus
Izzedine, H., Launay‐Vacher, V., Deybach, C., Bourry, E., Barrou, B., & Deray, G. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.6.1097 · Cited by 64
Role of Angiotensin and Its Inhibition in Hypertension, Ischemic Heart Disease, and Heart Failure
Gavras, H. P., & Brunner, H. R. (2001) · Hypertension · doi:10.1161/01.hyp.37.2.342 · Cited by 64
Konoshita, T. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0212-0 · Cited by 64
Abassi, Z. A., Winaver, J. M., & Feuerstein, G. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.018 · Cited by 64
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.745 · Cited by 64
Koulouris, S. N., Symeonides, P., Triantafyllou, K. A., Ioannidis, G., Karabinos, I. K., Katostaras, T., El-Ali, M., Theodoridis, T., Vratsista, E., Thalassinos, N., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.01.092 · Cited by 64
Zanchetti, A., Mancia, G., Black, H. R., Oparil, S., Waeber, B., Schmieder, R. E., Bakris, G. L., Messerli, F. H., Kjeldsen, S. E., & Ruilope, L. M. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283298ea2 · Cited by 63
Self-citationPreiss, D., Sattar, N. A., & McMurray, J. J. V. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.10.019 · Cited by 63
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points
Parving, H., Andersen, S., Jacobsen, P. K., Christensen, P. K., Rossing, K., Hovind, P. H., Rossing, P. R., & Tarnow, L. (2004) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2003.11.003 · Cited by 63
Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance
Henriksen, E. J., & Jacob, S. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00265.x · Cited by 63
Ghiadoni, L., Bruno, R. M., Stea, F., Virdis, A., & Taddei, S. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0034-5 · Cited by 63
Angiotensin II type 2 receptor agonists: where should they be applied?
Verdonk, K., Danser, A. H. J., & van Esch, J. H. M. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.664131 · Cited by 63
Role of AT1receptor-mediated salt retention in angiotensin II-dependent hypertension
Crowley, S. D., Zhang, J., Herrera, M., Griffiths, R., Ruiz, P., & Coffman, T. M. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00305.2011 · Cited by 63
Do angiotensin II receptor blockers increase the risk of myocardial infarction?
Verdecchia, P., Angeli, F., Gattobigio, R., & Reboldi, G. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi445 · Cited by 63
Adenosine signaling in diabetes mellitus and associated cardiovascular and renal complications
Peleli, M., & Carlström, M. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.12.001 · Cited by 63
Mörtsell, D., Malmqvist, K. K., Held, C., & Kahan, T. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01775.x · Cited by 63
Dhamrait, S. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00441-x · Cited by 62
Deletion of angiotensin II type I receptor reduces hepatic steatosis
Nabeshima, Y., Tazuma, S., Kanno, K., Hyogo, H., & Chayama, K. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.01.018 · Cited by 62
Vishram, J. K. K., Dahlöf, B., Devereux, R. B., Ibsen, H., Kjeldsen, S. E., Lindholm, L. H., Mancia, G., Okin, P. M., Rothwell, P. M., Wachtell, K., et al. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000739 · Cited by 62
Self-citationWeber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Velazquez, E., Gupte, J., Lefkowitz, M., Hester, A., Shi, V., Weir, M., et al. (2007) · Blood Pressure · doi:10.1080/08037050701217643 · Cited by 62
Self-citationβ-Blockers in Hypertension: Studies and Meta-analyses Over the Years
Larochelle, P., Tobe, S. W., & Lacourcière, Y. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.02.012 · Cited by 62
Hypertension and Cognitive Function in the Elderly
Cherubini, A., Lowenthal, D. T., Paran, E., Mecocci, P., WILLIAMS, L. S., & Senin, U. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2009.12.007 · Cited by 62
Capítulo 9 - Hipertensão Arterial na gestação
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Poli‐de‐Figueiredo, C. E., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160159 · Cited by 62
Profumo, E., Buttari, B., Saso, L., & Rigano, R. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666141203130324 · Cited by 62
Bönner, G., Bakris, G. L., Sica, D., Weber, M. A., White, W. B., Perez, A., Cao, C., Handley, A., & Kupfer, S. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.6 · Cited by 61
β blockers in hypertension and cardiovascular disease
Ong, H. T. (2007) · BMJ · doi:10.1136/bmj.39185.440382.47 · Cited by 61
The insulin resistance syndrome and coronary artery disease
Kendall, D. M., Sobel, B. E., Coulston, A. M., Harmel, A. L. P., McLean, B. K., Peragallo-Dittko, V., Buse, J. B., Fonseca, V. A., Hill, J. O., Nesto, R. W., et al. (2003) · Coronary Artery Disease · doi:10.1097/01.mca.0000076512.29238.2a · Cited by 61
The depressor axis of the renin–angiotensin system and brain disorders: a translational approach
Gironacci, M. M., Vicario, A., Cerezo, G., & Silva, M. G. (2018) · Clinical Science · doi:10.1042/cs20180189 · Cited by 60
Losartan Prevents Heart Fibrosis Induced by Long-Term Intensive Exercise in an Animal Model
Gay-Jordi, G., Guash, E., Benito, B., Brugada, J., Nattel, S., Mont, L., & Serrano-Mollar, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055427 · Cited by 60
Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
Standl, E., Schnell, O., & McGuire, D. K. (2016) · Circulation Research · doi:10.1161/circresaha.116.306924 · Cited by 59
Preventing Type II Diabetes Mellitus
Prisant, L. M. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004263018 · Cited by 58
Okin, P. M., Wachtell, K., Kjeldsen, S. E., Julius, S., Lindholm, L. H., Dahlöf, B., Hille, D. A., Nieminen, M. S., Edelman, J. M., & Devereux, R. B. (2008) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.108.795351 · Cited by 58
Self-citationTherapeutic potential of the renin angiotensin system in ischaemic stroke
Arroja, M. M. C., Reid, E., & McCabe, C. (2016) · Experimental & Translational Stroke Medicine · doi:10.1186/s13231-016-0022-1 · Cited by 57
Metadata
- Authors
- Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., & Wedel, H.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Oslo University Hospital (NO)
- University of Michigan (US)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- Glostrup Hospital (DK)
- Umeå University (SE)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Corresponding author
- Dahlöf, Björn
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 995-1003
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2133217116
- Cited by
- 5,407
- References
- 29
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 51 · 2023: 69 · 2022: 63 · 2021: 75 · 2020: 74 · 2019: 82 · 2018: 106 · 2017: 144 · 2016: 131 · 2015: 152 · 2014: 208 · 2013: 200 · 2012: 265
- FWCI
- 333.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- atenolol, essential hypertension, left ventricular hypertrophy, angiotensin receptor blockers, beta-blockers, cardiovascular morbidity, cardiovascular mortality, stroke, myocardial infarction, blood pressure reduction, new-onset diabetes, antihypertensive therapy, elderly patients, secondary prevention of cardiovascular disease, renin-angiotensin system blockade
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.